Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | CCNK | O75909 | 1/20 | 0.30 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26075131 | 0.84 | ITK (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4JAK3 | |
| SCHEMBL9070554 | 0.82 | ALDH1A1 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4JAK3 | |
| SCHEMBL31336075 | 0.82 | ALDH1A1 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4JAK3 | |
| SCHEMBL23450383 | 0.82 | ALDH1A1 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1 | |
| SCHEMBL9070664 | 0.79 | ALDH1A1 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA4CCNK | |
| SCHEMBL15951606 | 0.77 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4JAK3 | |
| SCHEMBL23653179 | 0.77 | CHRNB2 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA4JAK3 | |
| SCHEMBL12313552 | 0.76 | JAK3 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4JAK3 | |
| SCHEMBL14813244 | 0.76 | ALDH1A1 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4JAK3 | |
| SCHEMBL14813245 | 0.76 | ALDH1A1 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208388-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200172495-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208388-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | CHRNB2 4140/4885CHRNB4 4425/4885CHRNA3 4546/4885 |
| US-20200172495-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | CHRNB2 4140/4885CHRNB4 4425/4885CHRNA3 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.